Skip to search formSkip to main contentSkip to account menu

LEA29Y

Known as: LEA 29Y 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

abataceptbelatacept

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Cytokine‐inducible promoters to drive dynamic transgene expression: The “Smart Graft” strategy
Ubiquitous expression of T‐cell regulatory transgenes such as the cytotoxic T lymphocyte‐associated antigen 4 (CTLA4) or the high… 
2012
2012
How to Kill Two Birds With One Transgenic Pig
Islet transplantation promises to provide safe, long-lasting insulin independence to individuals with diabetes. Yet the need for… 
Review
2012
Review
2012
Immunotherapy for De Novo Renal Transplantation
Immunosuppressive drugs have been traditionally developed to prevent acute rejection and to improve short-term kidney transplant… 
2011
2011
Production and characterization of LEA29Y, a variant of cytotoxic T-lymphocyte antigen 4-immunoglobulin, in Pichia pastoris
Blocking the CD28/B7 costimulatory pathway is a promising strategy in the treatment of graft rejection, graft-versus-host disease… 
2011
2011
Quantitative analysis predicts the relative therapeutic efficacy of different forms of CTLA4Ig.
Review
2006
Review
2006
Immunotherapy for De Novo renal transplantation: what's in the pipeline?
Immunosuppressive drugs have been traditionally developed to prevent acute rejection and to improve short-term kidney transplant… 
Review
2005
Review
2005
Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen 4-immunoglobulin
Purpose of reviewBlockade of T cell costimulatory pathways has enormous potential as an immunosuppressive strategy to prolong the… 
2004
2004
CO-STIMULATION BLOCKADE WITH LEA29Y IN A CALCINEURIN INHIBITOR FREE MAINTENANCE REGIMEN IN RENAL TRANSPLANT: 6-MONTH EFFICACY AND SAFETY
Review
2002
Review
2002
What's in the Pipeline? New Immunosuppressive Drugs in Transplantation
In the pipeline, there are a number of novel immunosuppressive drugs in preclinical development or in early clinical trials. The… 
Review
2002
Review
2002
New developments in immunosuppressive therapy in renal transplantation
The introduction of new immunosuppressive agents and protocols has improved outcomes for renal transplant recipients by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)